Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Phase 3
Completed
NCT04248829
| Condition | Non-Small Cell Lung Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Yuhan Corporation |
|---|
| Status | Completed |
|---|
| Enrollment | 393 participants |
|---|
| Interventions | Lazertinib 240 mg/160 mg, Gefitinib 250 mg, Lazertinib-matching placebo 240 mg/160 mg, Gefitinib-matching placebo 250 mg |
|---|
| Start date | Feb 13, 2020 |
|---|
| Completion date | Jul 29, 2022 |
|---|
| Results posted | Mar 22, 2024 |
|---|
Summary
This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations
Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant. · Months
| Lazertinib 240 mg | 20.6 Months |
|---|
| Gefitnib 250 mg | 9.7 Months |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.